Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TK2 | O00142 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL8217370 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL8070613 | 1.00 | TK1 (0.65) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL176363 | 0.95 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL21682515 | 0.95 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL8075845 | 0.95 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL77830 | 0.95 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL887722 | 0.95 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL9386574 | 0.94 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL5692278 | 0.94 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL7576317 | 0.94 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223538-B2 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-29 | — | — | US | claimed |
| CN-1620515-A | Post-synthesis labeling of nucleic acids and uses thereof | AMERSHAM BIOSCIENCES AB (SE) | 2005-05-25 | — | — | CN | claimed |
| EP-1461455-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | Amersham Biosciences AB (SE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003052115-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-20030119005-A1 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | MOTOROLA, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4108670-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | disclosed |
| CN-115151555-A | Bridged nucleoside and nucleotide using the same | 国立大学法人大阪大学 | 2022-10-04 | — | — | CN | disclosed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3925965-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3919501-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-6051699-A | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5859232-A | Process for the synthesis of oligomeric phosphite, phosphodiester, phosphorothioate and phosphorodithioate compounds | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0886638-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0870194-A1 | CAPILLARY ELECTROPHORETIC SEPARATION METHOD USING A FILLABLE POLYMER SOLUTION AS SEPARATING AGENT | Novartis AG (CH) | 1998-10-14 | — | — | EP | disclosed |
| US-5705621-A | Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997038134-A1 | METHOD FOR DETECTING A TARGET COMPOUND USING A NUCLEIC ACID LIGAND | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997024610-A1 | CAPILLARY ELECTROPHORETIC SEPARATION METHOD USING A FILLABLE POLYMER SOLUTION AS SEPARATING AGENT | NOVARTIS AG (CH) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997019092-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | SLC29A1, SLC29A2, PNP | TK1 53/4885LMNA 1741/4885SMN1; SMN2 699/4885 |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | TK1 99/4885LMNA 1449/4885SMN1; SMN2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.